Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.

Mostoufi-Moab S, Labourier E, Sullivan L, LiVolsi V, Li Y, Xiao R, Beaudenon-Huibregtse S, Kazahaya K, Adzick NS, Baloch Z, Bauer AJ.

Thyroid. 2018 Jan;28(1):60-67. doi: 10.1089/thy.2017.0059. Epub 2017 Dec 11.

2.

Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations.

Wylie D, Beaudenon-Huibregtse S, Haynes BC, Giordano TJ, Labourier E.

J Pathol Clin Res. 2016 Feb 8;2(2):93-103. doi: 10.1002/cjp2.38. eCollection 2016 Apr.

3.

Letter to the Editor: The Value of Molecular Testing for Effective Management of Patients With Indeterminate Thyroid Nodules.

Labourier E.

J Clin Endocrinol Metab. 2016 Aug;101(8):L76-7. doi: 10.1210/jc.2016-2044. No abstract available.

PMID:
27486945
4.

Efficiency versus effectiveness: impact of molecular testing on healthcare costs and clinical outcome of patients with indeterminate thyroid nodules.

Labourier E.

Med Oncol. 2016 Jul;33(7):79. doi: 10.1007/s12032-016-0792-2. Epub 2016 Jun 15. No abstract available.

PMID:
27307224
5.

Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology.

Labourier E.

Clin Endocrinol (Oxf). 2016 Oct;85(4):624-31. doi: 10.1111/cen.13096. Epub 2016 Jun 3.

PMID:
27155136
6.

Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.

Labourier E, Shifrin A, Busseniers AE, Lupo MA, Manganelli ML, Andruss B, Wylie D, Beaudenon-Huibregtse S.

J Clin Endocrinol Metab. 2015 Jul;100(7):2743-50. doi: 10.1210/jc.2015-1158. Epub 2015 May 12.

7.

Conversion, correction, and International Scale standardization: results From a Multicenter External Quality Assessment Study for BCR-ABL1 testing.

Griffiths M, Patton SJ, Grossi A, Clark J, Paz MF, Labourier E; Labceutics International BCR-ABL1 Standardization Study Group.

Arch Pathol Lab Med. 2015 Apr;139(4):522-9. doi: 10.5858/arpa.2013-0754-OA. Epub 2014 Jul 25.

PMID:
25061833
8.

Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.

Giordano TJ, Beaudenon-Huibregtse S, Shinde R, Langfield L, Vinco M, Laosinchai-Wolf W, Labourier E.

Hum Pathol. 2014 Jul;45(7):1339-47. doi: 10.1016/j.humpath.2014.03.010. Epub 2014 Apr 4.

PMID:
24830619
9.

Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.

Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, Moore P, Andruss B, Labourier E.

Thyroid. 2014 Oct;24(10):1479-87. doi: 10.1089/thy.2013.0640. Epub 2014 Jun 18.

PMID:
24811481
10.

A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer.

Brand RE, Adai AT, Centeno BA, Lee LS, Rateb G, Vignesh S, Menard C, Wiechowska-Kozłowska A, Bołdys H, Hartleb M, Sanders MK, Munding JB, Tannapfel A, Hahn SA, Stefańczyk L, Tsongalis GJ, Whitcomb DC, Conwell DL, Morisset JA, Gardner TB, Gordon SR, Suriawinata AA, Lloyd MB, Wylie D, Labourier E, Andruss BF, Szafranska-Schwarzbach AE.

Clin Gastroenterol Hepatol. 2014 Oct;12(10):1717-23. doi: 10.1016/j.cgh.2014.02.038. Epub 2014 Mar 21.

PMID:
24662333
11.

A multiplex technology platform for the rapid analysis of clinically actionable genetic alterations and validation for BRAF p.V600E detection in 1549 cytologic and histologic specimens.

Smith DL, Lamy A, Beaudenon-Huibregtse S, Sesboüé R, Laosinchai-Wolf W, Sabourin JC, Labourier E.

Arch Pathol Lab Med. 2014 Mar;138(3):371-8. doi: 10.5858/arpa.2013-0002-OA. Epub 2013 Jun 28.

PMID:
23808402
12.

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E.

Clin Chem. 2013 Jun;59(6):938-48. doi: 10.1373/clinchem.2012.196477. Epub 2013 Mar 7.

13.

Do pre-analytical parameters explain KRAS test sensitivity disparities?

Labourier E.

J Mol Diagn. 2012 Nov;14(6):631-3; author reply 632-3. doi: 10.1016/j.jmoldx.2012.07.003. No abstract available.

PMID:
23059349
14.

An optimized technology platform for the rapid multiplex molecular analysis of genetic alterations associated with leukemia.

Ye F, Laosinchai-Wolf W, Labourier E.

Cancer Genet. 2012 Oct;205(10):488-500. doi: 10.1016/j.cancergen.2012.06.006. Epub 2012 Sep 29.

15.

Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: results from a multicenter validation study.

Gocke CD, Mason J, Brusca L, Laosinchai-Wolf W, Higgs C, Newell H, Masters A, Friar L, Karp J, Griffiths M, Wei Q, Labourier E.

Blood Cancer J. 2012 Jul;2(7):e78. doi: 10.1038/bcj.2012.24. Epub 2012 Jul 13.

16.

Human native lipoprotein-induced de novo DNA methylation is associated with repression of inflammatory genes in THP-1 macrophages.

Rangel-Salazar R, Wickström-Lindholm M, Aguilar-Salinas CA, Alvarado-Caudillo Y, Døssing KB, Esteller M, Labourier E, Lund G, Nielsen FC, Rodríguez-Ríos D, Solís-Martínez MO, Wrobel K, Wrobel K, Zaina S.

BMC Genomics. 2011 Nov 25;12:582. doi: 10.1186/1471-2164-12-582.

17.

Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale.

Brown JT, Laosinchai-Wolf W, Hedges JB, Watt CD, Van Deerlin VM, Fletcher L, Branford S, Labourier E.

Blood Cancer J. 2011 Mar;1(3):e13. doi: 10.1038/bcj.2011.10. Epub 2011 Mar 25.

18.

Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.

Laosinchai-Wolf W, Ye F, Tran V, Yang Z, White R, Bloom K, Choppa P, Labourier E.

J Clin Pathol. 2011 Jan;64(1):30-6. doi: 10.1136/jcp.2010.081539. Epub 2010 Oct 28.

PMID:
21030527
19.

Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations.

Hafez M, Ye F, Jackson K, Yang Z, Karp JE, Labourier E, Gocke CD.

J Mol Diagn. 2010 Sep;12(5):629-35. doi: 10.2353/jmoldx.2010.090219. Epub 2010 Jul 8.

20.

International standards and reference materials for quantitative molecular infectious disease testing.

Madej RM, Davis J, Holden MJ, Kwang S, Labourier E, Schneider GJ.

J Mol Diagn. 2010 Mar;12(2):133-43. doi: 10.2353/jmoldx.2010.090067. Epub 2010 Jan 14. Review.

21.

Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues.

Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ.

Clin Chem. 2008 Oct;54(10):1716-24. doi: 10.1373/clinchem.2008.109603. Epub 2008 Aug 21.

22.

Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling.

Szafranska AE, Davison TS, Shingara J, Doleshal M, Riggenbach JA, Morrison CD, Jewell S, Labourier E.

J Mol Diagn. 2008 Sep;10(5):415-23. doi: 10.2353/jmoldx.2008.080018. Epub 2008 Aug 7.

23.

Asuragen Inc.

Labourier E, Winkler M.

Pharmacogenomics. 2008 Jun;9(6):675-80. doi: 10.2217/14622416.9.6.675.

24.

Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues.

Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE.

J Mol Diagn. 2008 May;10(3):203-11. doi: 10.2353/jmoldx.2008.070153. Epub 2008 Apr 10.

25.

MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.

Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA.

Oncogene. 2007 Jun 28;26(30):4442-52. Epub 2007 Jan 22.

PMID:
17237814
26.

The colorectal microRNAome.

Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92. Epub 2006 Feb 27.

27.

An optimized isolation and labeling platform for accurate microRNA expression profiling.

Shingara J, Keiger K, Shelton J, Laosinchai-Wolf W, Powers P, Conrad R, Brown D, Labourier E.

RNA. 2005 Sep;11(9):1461-70. Epub 2005 Jul 25.

28.

RAS is regulated by the let-7 microRNA family.

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ.

Cell. 2005 Mar 11;120(5):635-47.

29.
30.

The KH-type RNA-binding protein PSI is required for Drosophila viability, male fertility, and cellular mRNA processing.

Labourier E, Blanchette M, Feiger JW, Adams MD, Rio DC.

Genes Dev. 2002 Jan 1;16(1):72-84.

31.
33.

Identification of two human nuclear proteins that recognise the cytosine-rich strand of human telomeres in vitro.

Lacroix L, Liénard H, Labourier E, Djavaheri-Mergny M, Lacoste J, Leffers H, Tazi J, Hélène C, Mergny JL.

Nucleic Acids Res. 2000 Apr 1;28(7):1564-75.

34.

Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives.

Moreau P, Anizon F, Sancelme M, Prudhomme M, Sevère D, Riou JF, Goossens JF, Hénichart JP, Bailly C, Labourier E, Tazzi J, Fabbro D, Meyer T, Aubertin AM.

J Med Chem. 1999 May 20;42(10):1816-22.

PMID:
10346933
35.

Recognition of exonic splicing enhancer sequences by the Drosophila splicing repressor RSF1.

Labourier E, Allemand E, Brand S, Fostier M, Tazi J, Bourbon HM.

Nucleic Acids Res. 1999 Jun 1;27(11):2377-86.

36.

Antagonism between RSF1 and SR proteins for both splice-site recognition in vitro and Drosophila development.

Labourier E, Bourbon HM, Gallouzi IE, Fostier M, Allemand E, Tazi J.

Genes Dev. 1999 Mar 15;13(6):740-53.

38.

A novel phosphorylation-dependent RNase activity of GAP-SH3 binding protein: a potential link between signal transduction and RNA stability.

Gallouzi IE, Parker F, Chebli K, Maurier F, Labourier E, Barlat I, Capony JP, Tocque B, Tazi J.

Mol Cell Biol. 1998 Jul;18(7):3956-65.

39.

The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity.

Rossi F, Labourier E, Gallouzi IE, Derancourt J, Allemand E, Divita G, Tazi J.

Nucleic Acids Res. 1998 Jun 15;26(12):2963-70.

40.
41.

DNA topoisomerase I: customs officer at the border between DNA and RNA worlds?

Tazi J, Rossi F, Labourier E, Gallouzi I, Brunel C, Antoine E.

J Mol Med (Berl). 1997 Nov-Dec;75(11-12):786-800. Review.

PMID:
9428609
42.

Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I.

Rossi F, Labourier E, Forné T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C, Tazi J.

Nature. 1996 May 2;381(6577):80-2.

PMID:
8609994
43.

Structural features of U6 snRNA and dynamic interactions with other spliceosomal components leading to pre-mRNA splicing.

Forné T, Labourier E, Antoine E, Rossi F, Gallouzi I, Cathala G, Tazi J, Brunel C.

Biochimie. 1996;78(6):436-42. Review.

PMID:
8915533
44.

Disruption of base-paired U4.U6 small nuclear RNAs induced by mammalian heterogeneous nuclear ribonucleoprotein C protein.

Forné T, Rossi F, Labourier E, Antoine E, Cathala G, Brunel C, Tazi J.

J Biol Chem. 1995 Jul 7;270(27):16476-81.

Supplemental Content

Loading ...
Support Center